---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-041619"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:27:36.812062+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Candel reports CAN-2409 phase 2 interim data: median OS 28.8 vs 12.5 months in pancreatic cancer

## Summary
- Estimated median overall survival 28.8 months for CAN-2409 group vs 12.5 months for control in borderline resectable PDAC.
- 24-month survival rate 71.4% for CAN-2409 vs 16.7% control; 36-month rate 47.6% vs 16.7%.
- 4 of 7 CAN-2409 patients alive at data cut-off (2 >50 months); only 1 of 6 control alive.
- Immune activation confirmed: dense CD8+ TILs, dendritic cells, B cells in tumor; increased granzymes and IFN-γ in blood.
- No dose-limiting toxicities or pancreatitis; FDA Fast Track Designation granted in December 2023.

## SEC filing metadata
- accession: 0000950170-24-041619
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/0000950170-24-041619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024041619/cadl-20240404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-041619
- JSON: https://secwatch.observer/filing/0000950170-24-041619.json
- Plain text: https://secwatch.observer/filing/0000950170-24-041619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.